|

CAR T-cell Therapy in Patients With Renal Dysfunction

RECRUITINGPhase 2Sponsored by Northside Hospital, Inc.
Actively Recruiting
PhasePhase 2
SponsorNorthside Hospital, Inc.
Started2024-11-18
Est. completion2026-08-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05909059

Summary

This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
* Adequate bone marrow function to receive lymphodepleting chemotherapy
* Renal function \</= 60mL/min/1.73m2
* ECOG 0-2

Exclusion Criteria:

* Relative CNS disorders
* Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
* Use of therapeutic dose systemic corticosteroids (defined as \>20mg/day prednisone or equivalent) within 72 hours of CAR-T administration

Conditions4

Acute Lymphoblastic Leukemia, AdultCancerMultiple MyelomaNon-hodgkin Lymphoma,B Cell

Locations1 site

Caitlin Guzowski
Atlanta, Georgia, 30342
Caitlin Guzowski, MBA, MHA404-851-8523caitlin.guzowski@northside.com

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.